Earnings per share for the last twelve months: Purple Biotech Ltd (PPBT)
Fierce competition with pharma behemoths for FDA approval is driving high volatility, as evidenced by the rolling net income per share. The value -28.27 shows the current magnitude of this indicator. Purple Biotech (PPBT) is currently focusing on R&D without commercial sales, and its growth potential is based on trials of agents against stomach tumor resistance.
Summary analytical data breakdowns for Purple Biotech Ltd (PPBT)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Purple Biotech|PPBT - Long-Term Debt to Capital|Short-Term Debt to Equity Purple Biotech Corp|PPBT - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Purple Biotech Ltd.|PPBT - Long-Term Liabilities|Company Short-Term Debt Purple Biotech|Quick Ratio purple-biotech.com
- net income and valuation multiples indicators:
PPBT - Company Net Income|Future Profit Purple Biotech|PPBT - Company Value to Net Income|Forward P/E Multiple Purple Biotech Ltd.|PPBT - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Purple Biotech Ltd.|PPBT - Operating income before deduction of amortization|Earnings per share for the last twelve months Purple Biotech|PPBT - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months purple-biotech.com|PPBT - Net earnings per one share growth for the current year|Earnings growth forecast for next year Purple Biotech
General company analysis:PPBT - Purple Biotech
Global partnerships of Purple Biotech (PPBT) allow the company to mitigate Israel's geopolitical risks while maintaining operational resilience. The metric is calculated as the ratio of total net income to the total number of shares outstanding. This calculation determines the real return per share, eliminating distortions from issuance. The investor assesses the business's sensitivity to the external environment without waiting for quarterly reports. The trend in per-share profit changes over the last 12 months confirms sales effectiveness.
Key competitors
ONC: Net earnings per share for the last 12 months|HALO - Net earnings per share (EPS TTM)|Revolution Medicines, Inc. (RVMD) - Earnings per share for the last twelve months|Ascentage Pharma Group International - Earnings per share for the trailing year|CGON (CG Oncology Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma Corp URGN|Earnings per share for the last twelve months Bicara Therapeutics Inc. (BCAX)|PSNL: Earnings per one share for the last 12 months|Erasca - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Delcath Systems Inc DCTH|YMAB - Earnings per share for the last twelve months|Earnings per share for the trailing year AURA (Aura Corp)|candeltx.com (CADL) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months ARAY (accuray.com)|Earnings per share for the last twelve months SELLAS Life Sciences Group, Inc.|Earnings per share for the last twelve months ACTU|Net earnings per share (EPS TTM) CTOR|HURA - Net earnings per one share for the last twelve months|Protara Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year FATE|Aadi Bio - Net earnings per share (EPS TTM)|TCRX: Earnings per share for the last twelve months|CSBR: Net earnings per share (EPS TTM)|XBIT - Net earnings per share for the last four quarters|Earnings per share for the last twelve months CEL-SCI Corp.|Net earnings per one share for the last twelve months ostherapies.com OSTX|Net earnings per share for the last 12 months RADX (Radiopharm Theranostics Limited)|Earnings per share for the last four quarters ARTV|Net earnings per share (EPS TTM) ANL (Adlai Nortye)|Veru Corporation (VERU) - Net earnings per one share for the last twelve months|Tempest Therapeutics - Net earnings per share (EPS TTM)|Xilio Therapeutics, Inc. (XLO) - Net earnings per share for the last 12 months|RENB: Net earnings per share (EPS TTM)|Mural Oncology - Earnings per share for the trailing year|Earnings per share for the last twelve months Kairos Pharma Limited|OnKure - Earnings per one share for the last 12 months|Earnings per share for the last twelve months CytoMed Therapeutics (GDTC)|CRIS: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) APLM (Apollomics)|Tharimmune Inc - Earnings per share for the last twelve months|ADVB: Net earnings per share for the last 12 months|Genprex Inc - Earnings per share for the last four quarters|CLDI: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Sunshine Biopharma Inc.|XBIO (Xenetic Biosciences Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Salarius Pharmaceuticals Inc|Earnings per share for the last twelve months American Oncology Network (AONC)|BeiGene Ltd - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) CKPT (Checkpoint Therapeutics)|ELEV - Net earnings per share for the last 12 months|iCAD Corp - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Ikena Oncology, Inc.|Notable Labs Inc. (NTBL) - Earnings per share for the last twelve months|Viracta Therapeutics, Inc. - Earnings per share for the trailing year|Net earnings per share for the last 12 months MOR|NAYA: Earnings per share for the trailing year|Net earnings per share (EPS TTM) AAPGV
